

## **LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**<PARTICULARS TO APPEAR ON THE OUTER PACKAGE>**

**{CARTON LABEL / BOX}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ENURACE 10, 10 mg tablets for dogs  
**FR:** ENURACE petit chien, comprimé  
(Ephedrine HCl)

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Per tablet 10 mg Ephedrine HCl.

**3. PHARMACEUTICAL FORM**

Tablets.

**4. PACKAGE SIZE**

60 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION**

**7. METHOD AND ROUTE OF ADMINISTRATION**

Oral, with food. 1-3 mg/kg/day divided in 2 doses.

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Not applicable

**9. SPECIAL WARNINGS**

Accidental ingestion by man, especially children, is dangerous. Read the package leaflet before use.

**10. EXPIRY DATE**

EXP month/year

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.  
Store in the original package.

Divided tablets should be returned in the original package and used in the subsequent dose. Close the cap to the click.

<b>12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS</b>
---

Disposal: read package leaflet.

<b>13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</b>
--

For animal treatment only – To be supplied only on veterinary prescription.

<b>14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”</b>
--

Keep out of the reach and sight of children.

<b>15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</b>
---

Ecuphar NV  
Legeweg 157-i  
8020 Oostkamp  
Belgium

<b>16. MARKETING AUTHORISATION NUMBER(S)</b>
--

TO BE COMPLETED

<b>17. MANUFACTURER’S BATCH NUMBER</b>
--

Batch YYP000

**<PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE>**

**{PAPER LABEL / POLYPROPYLENE CONTAINER}**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

ENURACE 10, 10 mg tablets for dogs

**FR:** ENURACE petit chien, comprimé  
(Ephedrine HCl)

**2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES**

Per tablet 10 mg Ephedrine HCl.

**3. PHARMACEUTICAL FORM**

Tablets

**4. PACKAGE SIZE**

60 tablets

**5. TARGET SPECIES**

Dogs

**6. INDICATION(S)**

**7. METHOD AND ROUTE OF ADMINISTRATION**

Read the package leaflet before use.

**8. WITHDRAWAL PERIOD**

Not applicable.

**9. SPECIAL WARNINGS**

Accidental ingestion by man, especially children, is dangerous. Close the cap to the click. Read the package leaflet before use

**10. EXPIRY DATE**

EXP month/year

**11. SPECIAL STORAGE CONDITIONS**

Do not store above 25°C.  
Store in the original container.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS.**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

For animal treatment only – To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”**

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Ecuphar NV, Oostkamp, Belgium

**16. MARKETING AUTHORISATION NUMBER(S)**

TO BE COMPLETED

**17. MANUFACTURER’S BATCH NUMBER**

Batch YYP000

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

UK, NL, IT, BE, DE, ES: **ENURACE 10, 10 mg tablets for dogs**

FR: **ENURACE petit chien, comprimé**

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

#### Marketing authorisation holder

Ecuphar NV  
Legeweg 157-i  
8020 Oostkamp  
Belgium

#### Manufacturer for the batch release

Ecuphar NV  
Legeweg 157-i  
8020 Oostkamp  
Belgium

ACE Pharmaceuticals BV  
Schepenveld 41  
3891 ZK Zeewolde  
The Netherlands

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

ENURACE 10, 10 mg tablets for dogs

**FR:** ENURACE petit chien

(Ephedrine HCl)

### 3. STATEMENT OF THE ACTIVE SUBSTANCES.

The product contains 10 mg Ephedrine HCl per tablet, corresponding with 8.1 mg Ephedrine. The tablet can be divided in two equal parts, each part containing 5 mg Ephedrine HCl.

### 4. INDICATION(S)

Treatment of unwanted loss of urine (urinary incontinence) due to too low tension in the circular muscles closing the urethra (urethral sphincter mechanism incompetence) in ovariohysterectomised female dogs.

### 5. CONTRAINDICATIONS

Do not use the product in dogs with increased pressure in the eye (glaucoma).

Do not use in case of hypersensitivity to Ephedrine or to any of the excipients.

### 6. ADVERSE REACTIONS

- Disorders of the heart and blood circulation (tachycardia, atrium fibrillation, stimulation of the heart activity; vasoconstriction).
- Stimulation of the central nervous system, leading to sleeplessness, excitation, anxiety and trembling of the muscles (muscle tremors).
- Panting.
- Dilatation of the pupils (mydriasis).



- Bladder infection (cystitis).
- Relaxation of the muscles of the lungs (bronchodilatation) and decrease of mucus release in the lungs (respiratory mucosal membranes).
- Reduction of the motion (motility) and tension (tone) of the intestinal wall.

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Ovariohysterectomised female dogs.

## 8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

For oral administration only.

Give a starting dose of 2 mg Ephedrine HCl / kg / day, divided in two oral doses.

Dose according to the following dosing scheme:

Weight (kg)	Dose (mg/day)	Dose (Number of tablets)		
		per day	1 <sup>st</sup> gift	2 <sup>nd</sup> gift
5	10	1	½	½
7,5	15	1 ½	½	1
10	20	2	1	1
12,5	25	2 ½	1	1 ½
15	30	3	1 ½	1 ½
17,5	35	3 ½	1 ½	2
For weights superior or equal to 20 kg, use a higher strength of the product.				

Desired therapeutic effect and occurrence of adverse effects have to be monitored approximately at 14 days, 1 month, 3 months and 6 months after the start. Based on the observed effect in comparison with the expected effect and taking into account the occurrence of adverse effects, the individual dose should be adjusted. The dose should be adjusted to find the lowest effective dose. Once the effective dose has been established, dogs should still be monitored at regular intervals, e.g. every six months.

The product should be administered before meals in a piece of food.

A maximum dose of 5 mg/ kg of bodyweight per day has to be respected.

## 9. ADVICE ON CORRECT ADMINISTRATION

Pregnant women should wear gloves.

## 10. WITHDRAWAL PERIOD

Not applicable.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the reach and sight of children.

Do not store above 25°C.

Store in the original container.

Return divided tablet in the original package and use this tablet in the subsequent dose. Close the cap to the click.

Do not use after the expiry date stated on the label after “exp.”.

## 12. SPECIAL WARNINGS

- Do not use the product in dogs under 5 kg bodyweight.
- This product is not suitable for treatment of inappropriate urination resulting of behaviour problems.
- As ephedrine is an alpha and beta adrenergic receptor agonist, the product should be used with caution in dogs with cardiovascular disease and only after a comprehensive risk/benefit analysis by the attending veterinarian.

The dog’s cardiovascular functionality should be carefully assessed before the start of the treatment with the product and it should be periodically monitored during the treatment.

In addition, a similar approach should be adopted in animals suffering from partial urethral obstruction, hypertension, diabetes mellitus, hyperadrenocorticism, hyperthyroidism or other metabolic disorders. It should be mentioned that the Polyuria/Polydipsia (PU/PD) frequently accompanying the aforementioned conditions may be falsely diagnosed as urinary incontinence.

- Ephedrine may interact with other sympathicomimetics.
- Ephedrine may enhance the metabolism of hormones of the pituitary gland (glucocorticoid metabolism).
- Concomitant use with MAO-inhibitors (used for treatment of depression) may cause increased blood pressure (hypertension).
- Ephedrine can enhance the activity of products of the same class as theophyllin (used in treatment of epilepsy).
- Volatile anaesthetics may enhance the sensitivity of the heart muscle (myocardium) to the effects on heart and blood vessels (cardiovascular effects) of Ephedrine.
- Concomitant use with cardiac glycosides (used to increase the pump force of the heart), quinine (anti-infection) and tricyclic antidepressants (used for treatment of depressions) can cause disorders of the heart rhythm (arrhythmias).
- Constrictions of the blood vessels (vascular constrictions) can occur after concomitant treatment with ergot alkaloids and oxytocin (both used for the induction of labour).
- Substances leading to an increase in pH of the urine are able to prolong the excretion of ephedrine, whereas substances leading to a decrease in pH of the urine are able to accelerate the excretion of ephedrine.

The signs of overdose resemble those of the adverse reactions as described in section 6. In case of overdose, it is useful to accelerate excretion of ephedrine by acidification of the urine and enhanced diuresis.

### Warnings on accidental ingestion

Ephedrine hydrochloride could be toxic if ingested. Adverse effects may include insomnia and nervousness, dizziness, headache, increased blood pressure, increased sweating and nausea.

Ingestion may be fatal, especially in children. To avoid accidental ingestion, the product must be used and kept out of the reach of children. Always replace the cap securely after use.

In the event of accidental ingestion, most importantly by children, seek immediate medical attention showing the physician the package insert.

It is strongly recommended that pregnant women should wear gloves for administration.

Wash hands after administration.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

TO BE COMPLETED

**15. OTHER INFORMATION**

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.